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ABSTRACT
Relatively little attention has been paid to ADP-ribosylated modifications of 
histones, especially to mono-ADP-ribosylation. As an increasing number of mono-
ADP-ribosyltransferases have been identified in recent studies, the functions of mono-
ADP-ribosylated proteins have aroused research interest. In particular, histones 
are substrates of some mono-ADP-ribosyltransferases and mono-ADP-ribosylated 
histone have been detected in physiological or pathological processes. In this 
research , arginine-117 (Arg-117; R-117) of hsitone3(H3) is identified as the a site 
of mono-ADP-ribosylation in colon carcinoma(the first such site to be identified); 
this posttranslational modification may promote the proliferation of colon carcinoma 
cells in vitro and in vivo. Using a point-mutant lentivirus transfection and using an 
activator of P300 allowed us to observe the mono-ADP-ribosylation at H3R117 and 
enhancement of the activity of P300 to up-regulate the level of acetylated β-catenin, 
which could increase the expression of c-myc and cyclin D1.
INTRODUCTION
Epigenetics are widely reported to play a major 
role in early stages of neoplastic development and in the 
whole process of progression of cancer [1]. Compared 
with the early focus on the DNA as a critical epigenetic 
marks in progression of cancer, a growing body of 
research now pays attention to the function of histone 
modifications in tumourigenesis [2]. Modifications 
of histones include acetylation, phosphorylation, 
methylation, ADP-ribosylation, ubiquitylation and 
sumoylation, amongst which acetylation of histones 
has already been confirmed in the regulation of various 
cancers. As more mono-ADP-ribosyltransferases have 
been found in recent years [3-7], the function of mono-
ADP-ribosylation of histones in the development of 
human disease, even in cancer, comes into view.
Histones are basic proteins ,which bind to anionic 
DNA in chromosomes.In eukaryotes, there are five types 
of histone: H1, H2A, H2B, H3 and H4. There is strong 
evidence that shows that poly-ADP-ribosylation of histones 
plays important roles in repair and replication of DNA [8, 
9] and in proliferation of cells and tumors [10]. Poly(ADP-
ribosyl)ation interacts with acetylation [11], methylation 
[12], phosphorylation [13] of hsitones. Increasing numbers 
of mono-ADP-ribosyltransferases have been detected 
in mammals and these have the potential to catalyze the 
mono-ADP-ribosylation of histones. However, research 
data on the role of mono-ADP-ribosylation in physical or 
pathological process are lacking to date.
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Nicotine-amide adenine dinucleotide (NAD+), 
a well-known coenzyme in redox reactions, is also an 
important substrate of mono-ADP-ribosylation. One ADP-
ribose is transferred to specific amino-acids (arginine, 
histidine, cysteine and asparagine) on target proteins, in 
processes catalyzed by mono-ADP-ribosylatransferasees 
[4, 14-15]. In our previous study, we showed that 
changing the expression of arginine-specific mono-ADP-
ribosylatransferasees affects the proliferation migration 
and adhesion of cells in colorectal cancer [16-18]. This 
suggests that mono-ADP-ribosylation plays an important 
role in the development of colorectal cancer. However, 
mono-ADP-ribosylation at different specific amino-acids 
sites of histones may cause different functional effects. A 
study of mono-ADP-ribosylation would clarify the exact 
mono-ADP-ribosylated amino-acid site its function in 
the development of cancers. We show here that H3R117 
is mono-ADP-ribosylated in highly malignant colon 
carcinoma cells (LOVO cell line), while this does not 
occur in a colon carcinoma of much lower malignancy 
(SW480 cell line). Our research indicates that H3R117 
mono-ADP-ribosylation enhances the activity of P300 to 
promote the proliferation of colon carcinoma.
RESULTS
Histone H3R117 is mono-ADP-ribosylated in 
highly malignant LOVO cells
The histones of LOVO cells and SW480 cells, 
which include H1, H2A, H2B, H3 and H4, were separated 
by SDPS-PAGE (Figure 1A). Normal distribution 
graphics of mass error distribution of peptide showedthat 
the fragment ions from histones of LOVO and SW480 
could match simulation peptides in a data bank (Figure 
1B). LC-MS/MS demonstrated that mono-ADP-
ribosylation at arginine would be produced ADP-R-
carbodiimide in the mass spectrometer, leading to an 
informative MS/MS mass spectrum (Table 1) and the 
number of peptides, proteins and sites where occurred 
mono-ADP-ribosylation occured(Table 2). MS/MS 
spectrum of the peptide precursor ions at m/z 584.4 
determining mono-ADP-ribosylation at arginine 117 in 
the peptide of 99AYLVGLFEDTNLCAIHAKR 117 of 
histone H3 (Protein ID IPI00455457) which e-value is 
0.0039(Figure 1C).
The construction of H3R117A and H3R117K 
LOVO cells
PLenti-H3 mut1-IRES-Egfp-and pLenti-H3 mut2-
IRES-Egfp-transfected LOVO cells were detected by 
the green fluorescence after the fourth day. The highest 
multiplicity of infection (MOI) was 20 (Figure 2A). After 
disposed basticidin (BSD) at the optimal concentration 
(4 μg/mL), the green fluorescence of H3R117A, H3R117K 
and blank load transfection LOVO cells were raised up 
to 80 % (Figure 2B). H3R117A, H3R117K, blank load 
transfection and non-transfection LOVO cells were 
prepared for follow-up experiments.
Effects of mono-ADP-ribosylation of histone 
H3R117 on proliferation of LOVO cells in vivo 
and in vitro
In order to investigate the function of H3R117 
mono-ADP-ribosylation on the proliferation of LOVO 
cells, a cell counting kit-8 (CCK-8) assay was used to 
measure cell viability. This is showed the proliferation 
inhibitory rate of LOVO cells increased when the R117 
acid of H3 was changed to alanine (A) or lysine (K) 
(p<0.05) (Figure 3A). The soft agar cloning method 
also showed that, compared with non-transfection group 
and blank load transfection group, the H3R117A and 
H3R117K groups formed fewer cell clones(p<0.001) 
(Figure 3B&3C). However, there is no difference between 
the H3R117A and H3R117K groups, indicating that the 
change of proliferation rate was effected by mono-ADP-
ribosylation at H3R117. To test the effect further, the cell 
cycles in each group were assessed by flow cytometry. The 
proliferation index(PI) of H3R117A and H3R117K group 
have a decrease compared with the control groups(p<0.05) 
(Figure 3D&3E). H3R117 mutant LOVO cells were also 
transplanted subcutaneously into nude mice. the weight 
and volume of transplanted tumors in the H3R117A and 
H3R117K groups were both less than for the control nude 
mice which were transplanted with wild-type LOVO cells 
(p<0.01) (Figure 3F&3G)
H3R117 mono-ADP-ribosylation is associated 
with P300 in the proliferation of LOVO cells
Quantitative real-time PCR (Q-PCR) was performed 
for detecting the mRNA of P300 between the amino-acid-
mutant groups and the control groups. Compared with the 
non-transfection group and the blank-load transfection 
group, a notable and highly significant finding is that the 
mRNA expression of P300 in the amino-acid-mutation 
groups is decreased (p<0.01) (Figure 4A). However, 
there was no significant difference between H3R117A 
and H3R117K groups (p>0.05). To verify further that 
H3R117 mono-ADP-ribosylation could influence the 
histone acetyltransferase activity of P300, P300 histone 
acetyltransferase activity was measured. We noted that 
the P300 histone acetyltransferase activity is decreased in 
H3R117A and H3R117K groups,relative to the wild-type 
(p <0.001) (Figure 4B)
The effect of mono-ADP-ribosylation H3R117 on 
proliferation via P300 was confirmed further. An activator 
of P300 (10 μM CTBP, N-[4-chloro-3-(trifluoromethyl)
phenyl]-2-ethoxy-6-pentadecylbenzamide) was used 
to treat the H3R117 mutant group for 24 h, and then 
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the proliferation of LOVO cells was measured. The 
change of P300 mRNA level between mutant groups 
treated with 10UM CTPB for 24h and mutant groups 
without CTPB was assessed by Q-PCR assay. Compared 
with mutant groups without CTPB, the P300 mRNA 
level showed increases in the mutant groups treated 
with CTPB (p<0.001), which illustrates the CTPB 
could increase the amount of P300 protein in mutant 
LOVO cells. Correspondingly, there was no significant 
difference between these two mutant groups treated 
Figure 1: LC-MS/MS analyzed that arginine mono-ADP-ribosylation of histone. (A) The histone of LOVO and SW480 was 
showed by SDSP-PAGE. (B) The errors distributions of confidence detected peptides. (C) MS/MS spectrum of the peptide precursor ions 
at m/z 584.4 determining mono-ADP-ribosylation at arginine 117 in the peptide of 99AYLVGLFEDTNLCAIHAKR 117 of histone H3.
Table 1: Total second stage mass spectrum y and meaningful second stage mass spectrum
Sample The number of Total second 
stage mass spectrum
The number of meaningful 
second stage mass spectrum
Spectrum identification rate
SW480-T 29209 532 1.82%
LOVO-T 29963 346 1.15%
SW480-G 24542 641 2.61%
LOVO-G 27189 467 1.72%
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with CTPB(p>0.05) (Figure 4C). Then, to test whether 
the proliferation of H3R117A and H3R117K LOVO 
cells lacking the mono-ADP-ribosylated modification 
on H3R117 could be regulated by the activity of P300, 
a CCK8 assay was performed. These results showed 
an increase of growth rate in the mutant groups treated 
with CTPB compared to the mutant groups without 
CTPB(P<0.05) (Figure 4D). FCM also showed that the 
PI of mutant groups was increased after treating with 
CTPB(p<0.05) (Figure 4E&4F). Together, these results 
suggest that mono-ADP-ribosylation at H3R117 regulates 
the proliferation of LOVO cells, possibly through P300.
Adjustment of H3R117 mono-ADP-ribosylation 
or P300 affect the expression c-myc and cyclinD1 
proteins in vivo and in vitro
The mechanism by which mono-ADP-ribosylation 
at H3R117 could regulate the proliferation of LOVO cells, 
in connection with P300, was unclear. Western blotting 
Table 2: The number of mono-ADP-ribosylated peptide, protein and site
Sample Peptide NO mono-ADP-ribosylated 
peptide NO
mono-ADP- ribosylated 
peptide Raito
Protein NO mono-ADP-ribosylated 
protein NO
mono-ADP- ribosylated 
protein Raito
mono-ADP- ribosylated 
site NO
SW480-T 382 7 1.83% 185 7 3.78% 7
LOVO-T 262 5 1.91% 134 5 3.73% 5
SW480-G 458 4 0.87% 230 4 1.74% 4
LOVO-G 350 6 1.71% 186 5 2.69% 6
Figure 2: H3R117A and H3R117K LOVO cells were constructed successfully. (A) Lentiviral infecting efficiency of LOVO 
cells was observed under under the microscope (× 200). (B) The expression rate of GFP in LOVO cells was detected by flow cytometry after 
transfection. Non-transfection group (P3=0.23%); Blank load transfection group (P3=76.66%); H3R117A group (P3=86.15%); H3R117K 
group (P3=76.69%).
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Figure 3: H3R117 mono-ADP-ribosylation affects the proliferation of colon carcinoma. (A) The proliferation inhibitory 
rate of mutant groups increased(*p<0.05). (B&C) The soft agar cloning method showed that the mutant groups formed fewer cell clones, 
compared with the control groups(***p<0.001). (D&E) FCM showed that the proliferation index(PI) of the mutant groups were lower 
than for the control groups(*p<0.05). (F&G) The weight and volume of mutant LOVO cells transplanted tumors in nude mice showed a 
significant reduction, compared with the control groups(**p<0.01).
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Figure 4: H3R117 mono-ADP-ribosylation effects on proliferation associates with P300. (A) The mean mRNA expression 
of P300 in H3R117A and H3R117K LOVO cells showed a reduction in contrast with the control groups(**p<0.01). (B) The P300 histone 
acetyltransferase activity kit detect that the activity of P300 is decreased in H3R117A and H3R117K LOVO cells(***p<0.001). (C) The 
mRNA level of P300 was raised in the mutant groups after treatment with CTPB (***p<0.001). (D-F) An increase of growth rate and PI in 
the mutant groups after treatment with CTPB (*p<0.05).
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Figure 5: Adjustment of H3R117 mono-ADP-ribosylation or P300 affects β-catenin, c-myc and cyclinD1. (A & B) Effects 
on the change of protein expression level in each LOVO cells group. Expression of c-myc and cyclin D1 in the LOVO cells groups showed 
a significant decrease in the mutant groups compared with the control LOVO groups (*p<0.05, ** p<0.01). (C & D) Proteins were extracted 
from nude mouse transplanted tumor tissues. The results of protein expression in vitro were in accordance with in vivo (*P<0.05). (E&F) 
Western blots showed that the expressions of c-myc and cyclinD1 in the mutants treated with CTBP groups were significantly increased 
compared with the mutant groups without CTBP (*p<0.05,** p<0.01).
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experiments showed that, both in vivo and in vitro, the 
expressions of proliferation-related regulators (c-myc, 
cyclinD) in the H3R117A and H3R117K group were 
lower than in the control groups (p<0.05) (Figure 5A-
5D). Correspondlingly, treatment of the H3R117A and 
H3R117K groups with the P300 activatorCTPB to caused 
expressions of c-myc and cyclinD to be increased (Figure 
5E&5F). Mono-ADP-ribosylation at H3R117 possibly 
regulates these proliferation-related regulators through 
P300. It is known that P300 would catalyze acetylation of 
β-catenin, which could affect the expression of important 
proliferation-related proteins c-myc and cyclinD1. A co-
immunoprecipitation assay was adopted to detect how the 
H3R117 mono-ADP-ribosylation affects the interaction 
between p300 and β-catenin. The change of H3R117 
mono-ADP-ribosylation could affects the connection 
between acetylated β-catenin and P300 (Figure 6A&6B). 
Both in vivo and in vitro, the expression of β-catenin 
decreased in the H3R117A and H3R117K groups (P<0.05) 
(Figure 6C-6F). After treatment with the P300 activator 
CTPB , the expression of β-catenin also was increased 
in the H3R117A and H3R117K groups (Figure 6G&6H). 
Hence, mono-ADP-ribosylation at H3R117 may regulate 
the activity of P300 in catalyzing the acetylation of 
β-catenin and thus affect the amount of β-catenin protein.
DISCUSSION
Post-translational mechanism is a vital process 
in modification of proteins,with consequent regulation 
of the activity or function of the target proteins. Mono-
ADP-ribosylation is one post-translational modifications 
involved in regulation of development of colorectal cancer. 
Arginine-specific mono-ADP-ribosyltransferase1(ART1), 
one of several mono-ADP-ribosyltransferase, has been 
reported to play an important role in various diseases 
[19-22]. Our previous studies have shown that ART1 is 
associated with apoptosis, proliferation and migration 
of colon carcinoma CT26 cells [19, 23, 24]. In addition, 
ART1 is associated with angiogenesis in human 
colorectal carcinoma tissues [25]. We knew that mono-
ADP-ribosylation promotes the development of colon 
carcinoma, although the specific mono-ADP-ribosylatied 
amino acid site and target protein was not clear. This is 
indeed the challenge in studying the detailed effects of 
this post-translational modification and its influence on 
signaling pathways. Moreover, it contributes to provide 
a theoretical basis for the therapeutic approaches against 
various diseases [26-28]. We employed LC-MS/MS to 
analyze the site of mono-ADP-ribosylated modification 
on histone3 in different malignant cell lines and were 
pleased to find that this histone is mono-ADP-ribosylated 
only in the highly malignant colon carcinoma cell line 
(LOVO cells). One of these sites is H3R117. To detect 
the function of mono-ADP-ribosylation of H3R117 in 
colon carcinoma, we changed the arginine to other amino-
acids (lysine or alanine); the mono-ADP-ribosylation is 
specific to arginine as the target amino-acid. Effects on 
the proliferation of LOVO cells were observed. Previous 
research had shown that the levels of mono-ADP-
ribosylated histones changed in mouse mastocytoma 
P815 and human chronic myelogenous leukemia K562 
cells treated with 5 mM butyrate or serum-free media 
to block proliferation. Furthermore, it is suggested that 
the mono-ADP-ribosylation is the first stage of the poly-
ADP-ribosylated histones which have been detected 
in rapidly dividing cells [29]. Mono-ADP-ribosylated 
histone may be an important regulative factor in cellular 
proliferation. In present study, the data showed that the 
cell growth inhibition ratio increased and the proliferation 
index reduced in H3R117A and H3R117 modified LOVO 
cells; Moreover, the weight and volume of tumors derived 
from these H3R117A and H3R117 LOVO cells after 
subcutaneous transplantation in nude mice were both 
decreased. These results indicate that arginine-specific 
mono-ADP-ribosylation of H3R117 might regulate the 
proliferation of LOVO cells.
Several studies have shown that different types of 
post-translational modification of histones not only affect 
the interactions with the proteins, but also could interplay 
mutually. Studies have shown that, when an acetylation 
of a histone is detected, it is occasionally accompanied 
by mono-ADP ribosylation modification which suggests 
an interaction between acetylation and mono-ADP 
ribosylation of histones. However, the mechanism needed 
to be elucidated. The transcriptional co-activators CREB 
binding protein (CBP) and p300 are members of the 
histone acetyltransferase(HAT) family. CBP is highly 
homologous with P300. CBP and P300 have been reported 
to acetylate histones and non-histone proteins, which 
result in different effects on gene transcription [30-35]. 
The effects of P300 have been proven to be involved in 
cell cycle regulation, cell differentiation and cell apoptosis 
[36, 37]. Activated poly-(ADP-ribose) polymerase 1 
(PARP1) can upregulate the activity of acetyltransferase of 
P300 [38]. In our previous studies, both arginine-specific 
mono-ADP-ribosyltransferase1 (ART1) and poly-(ADP-
ribose) polymerase 1 (PARP1) were shown to promote 
the development of colon carcinoma (CRC). PARP-1 is 
affected by regulation of ART1 through NF-κB [39]. In 
addition, there is a synergistic effect of ATR1 and PARP-1 
on the apoptosis induced by cisplatin in CT26 cells. PARP-
1 was found downstream of ART1, which suggests PARP-
1 activity may be modulated by ART1. Additionally, the 
histone mono-ADP-ribosylation reaction is the basis of 
the poly-(ADP-ribosyl)ation rections which regulate the 
cell proliferation [40]. Accordingly, we speculate whether 
the mono-ADP-ribosylation at H3R117 could affect 
P300. We observed that the production of mRNA and the 
histone acetyltransferase activity of P300 in the H3R117 
mutation groups is decreased. Hence, H3R117 mono-
ADP-ribosylation may be connected with P300.
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Moreover, studies have reported that P300 can 
interplay with β-catenin and the interaction between 
P300 and β-catenin makes influences Wnt signaling 
pathway in regulation of the cell physiology, including 
the proliferation, differentiation and apoptosis of colon 
carcinoma(CRC) cells [41-45]. In addition, in colon 
carcinoma, the interaction of P300 with β-catenin has 
important impacts on the development of colon cancer 
cells [46-48]. Therefore, we investigated whether mono-
ADP-ribosylation at H3R117 promotes proliferation of 
Figure 6: Adjustment of H3R117 mono-ADP-ribosylation or P300 affect β-catenin and the interaction of P300 and 
acetylation β-catenin. (A&B) Effects on the interaction of P300 and acetylation β-catenin between the mutant groups and the control 
groups in vivo or in vitro. Western blot analysis was conducted on the β-catenin immune complex with specific anti-acetylated lysine 
antibody. β-catenin was immunoprecipitated from each LOVO cells as an input by Western blot. (C-H) The changes of β-catenin expression 
in H3R117 mutant groups and in mutant groups with CTBP or not (***p<0.001).
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LOVO cells via P300. We added an activator of P300 
(CTBP) into H3R117A and H3R117K LOVO cells to re-
activate the P300 and observed that the proliferation index 
of H3R117A and H3R117K LOVO cells both increased. 
This is a preliminary indication that mono-ADP-
ribosylation at H3R117 dosed enhance the proliferation of 
LOVO cells via P300.
Studies have also reported that P300 can acetylate 
β-catenin to enhance the transcription of β-catenin and 
promote the combination of β-catenin with transcription 
factor 4 (TCF4), resulting in activating the Wnt/β-catenin 
signaling pathway [43, 45, 46, 48]. β-catenin acts as a 
vital part of the Wnt pathway, through activating the 
signaling pathway resulting in various human diseases 
including cancer. It is reported extensively that the Wnt 
pathway regulates growth, proliferation and apoptosis 
of cells. C-myc and cyclin D1 are downstream of the 
Wnt pathway relating to the proliferation of cancer cells. 
P300 acetylates β-catenin at lysine 49, which is reported 
frequently in cancer. Importantly, mutation of this site lead 
to an activation of c-myc gene through the augmentatiion 
of β-catenin [46]. In addition, β-catenin regulates the 
expression of cyclinD1 in colon carcinoma cells [49]. 
In the present study, our results are consistent with these 
reports. The expression of β-catenin, c-myc and cyclin D1 
was diminished in the H3R117A and H3R117K groups, 
which implies that the mono-ADP-ribosylation at H3R117 
has an effect on up-regulating the expression of β-catenin, 
c-myc and cyclin D1, the vital proliferation relative 
proteins. However, the specific mechanisms of these need 
to be further determined. To elaborate the mechanisms 
in more detail, we also added CTPB to H3R117 mutant 
LOVO groups and observed that the expression of 
β-catenin, c-myc and cyclin D1 were all increased. These 
results point towards the conclusion that H3R117 mono-
ADP-ribosylation may increase the proliferation-related 
proteins β-catenin, c-myc and cyclin D1 via P300.
In addition, to verify how H3R117 mono-ADP-
ribosylation impacts the combination of the P300 and 
β-catenin, a co-immunoprecipitation assay was showed 
how change of H3R117 mono-ADP-ribosylation could 
affect the connection between acetylated β-catenin, 
which detected by anti-acetyl-lysine antibody, and P300. 
It has been reported that P300 interacts with β-catenin in 
multiprotein complexes which could catalyzed acetylation 
of β-catenin. An anti-acetyl-lysine Western blot is more 
sensitive for detecting β-catenin acetylation [46, 50]. In 
addition, because acetylation of β-catenin can enhance 
the transcription of β-catenin, increase in acetylation of 
β-catenin could enhance the expression of β-catenin. We 
also noted that the expression of β-catenin decreases in 
the H3R117 mutant LOVO groups. Addition of CTBP into 
these cells led to increase in the expression of of β-catenin. 
This indicates that H3R117 mono-ADP-ribosylation 
influences the proliferation proteins c-myc and cyclin D1 
through the acetylation of β-catenin by P300.
In our study, we detect firstly the site of mono-ADP-
ribosylation on H3 in colon carcinoma cells and focus on 
the function of arginine site of mono-ADP-ribosylation 
modification in the proliferation of these cells. In addition, 
we study the possible molecular mechanisms in detail; it 
appears that H3R117 mono-ADP-ribosylation enhances 
the activity of acetyltransferase P300 activity towards 
β-catenin, leading to activation of downstream genes 
(c-myc, cyclin D1). However, the detail of how H3R117 
mono-ADP-ribosylation affects P300 remains to be 
studied. Nevertheless, our findings on the role of H3R117 
mono-ADP-ribosylation on colon carcinoma may lead to 
identification of a target for individualized treatment of 
colon cancer.
MATERIALS AND METHODS
Cell lines, reagents and animals
Human colon adenocarcinoma LOVO cells line and 
SW480 cells line obtained kind gift from Professor Wei-
Xue Tang, Chongqing Medical University (Chongqing, 
China). They were cultured in dulbecco’s modified 
eagle medium (DMEM) medium (Hyclone, Logan, UT, 
USA) with 10 % fetal bovine serum(Hyclone) under the 
conditions of 5 % CO2 and 37 °C. 10 μM CTPB [N-(4-
chloro- 3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-
benzamide] (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) was added to the cells for 24h. Nude mice were 
provided by the Experimental Animal Center of National 
Bio-industry Base in Chongqing Medical University.
LC-MS/MS screening the mono-ADP-
ribosylatied site on histones
This study was completed by the BGI-Huada 
Genomics Institute (Shenzhen, China). Cultured cells 
(5×106 cells/ mL) in 1.5 mL tubes. The method of 
Schechter was used for extraction of histones [51]. 
The supernatant was removed carefully with a pipette 
and the histone pellet was air-dried for 20 min at room 
temperature. The pellet was dissolved in an appropriate 
volume of double-distilled H2O (typically 100 mL). 
Histones were stored frozen at 80 °C before use the 
concretion of histones was assayed by the Bradford 
method. The histones from LOVO and SW480 cells were 
separated on a 12% SDS-PAGE gel and stained with 
Coomassie Brilliant Blue solution. 50 ug of histone from 
LOVO or SW480 was denatured by 8 M urea and then 
processed by reductive alkylation(DTT/IAM). The sample 
was diluted until the concentration of urea was diminished 
to 2 M and each sample was divided into two parts. The 
one part, which was labelled SW480-T or LOVO-T, was 
added trypsin (trypsin/protein =1:100) and the samples 
were incubated for 5 min at 37°C. 0.5% formic acid was 
added to terminate the reaction. To the other part, which 
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was labelled SW480-G or LOVO-G, was added Glu-C 
(Glu-C: trypsin=1:100) and the mixture was incubated for 
20 min overnight. Again, 0.5% formic acid was added to 
terminate the reaction. The derived mixture of peptides 
was desalted with C18 column, dried by vacuum-pumping 
and re-dissolved with 20 μL 0.1% formic acid. The quality 
was controlled by Matrix-Assisted Laser Desorption 
Ionization (MALDI) mass spectrometry and the peptides 
were then detected by LC-MS/MS (TripleTOF™ 5600, 
AB SCIEX, Boston, MA, USA). The software Mascot 
v2.3 was used to search the protein and the site of arginine 
mono-ADP-ribosylation in the mass spectral database IPI 
human v3.87. The parameters are as follows:
Construction of point-mutated H3R117 LOVO 
cells
The H3R117 point mutation sequence was designed 
and synthesized by Geneart (Regensburg, Germany). The 
sequence to change the H3 Arg-117 to alanine(H3R117A) 
is as follows: GGATCCaccatggcccgtactaagcagactgcccgc
aagtcgaccggcggcaaggccccgaggaagcagctggctaccaaagcggc
ccgcaagagcgcgccggccacgggcggggtgaagaagccgcaccgctacc
ggcccggcaccgtggctctgcgggagatccggcgctatcagaagtctacgga
gctgctgatccgcaagctgcccttccagcggctggtacgcgagatcgcgcag
gagtttaagacggacctgcgcttccagagctcggccgtgatggcgctgcagga
ggccagagaggcctacctggtggggctgttcgaagacacgaacctgtgcgcc
atccatgccaagGCCgtgaccatcatgcccaaggacatccagttggtcagcc
gcatccgcggggagcgggcctgaGGCGCGCC. The sequence of 
change the H3 117th arginine to lysine(H3R117K) is as 
follows: GGATCCaccatggcccgtactaagcagactgcccgcaagtc
gaccggcggcaaggccccgaggaagcagctggctaccaaagcggcccgca
agagcgcgccggccacgggcggggtgaagaagccgcaccgctaccggccc
ggcaccgtggctctgcgggagatccggcgctatcagaagtctacggagctgct
gatccgcaagctgcccttccagcggctggtacgcgagatcgcgcaggagttta
agacggacctgcgcttccagagctcggccgtgatggcgctgcaggaggccag
agaggcctacctggtggggctgttcgaagacacgaacctgtgcgccatccatg
ccaagAAAgtgaccatcatgcccaaggacatccagttggtcagccgcatccg
cggggagcgggcctgaGGCGCGCC. The two sequences were 
respectively wrapped with pLenti6.3_MCS_IREs2-EGFP 
and named pLenti-H3 mut1-Ires-EGFP or pLenti-H3 
mut2-Ires-EGFP, which were constructed by Invitrogen 
(Shanghai, China). LOVO cells were transfected with 
pLenti-H3 mut1-Ires-EGFP and pLenti-H3 mut2-Ires-
EGFP to construct H3R117A and H3R117K site-directed 
mutation LOVO cells.
Cell counting kit-8 (CCK-8) assay
100 μL of LOVO cells (5×103 cells per well) were 
dispensed in 96-well plates and respectively incubated for 
24 h, 48 h, 72 h, 96 h, 120 h under appropriate conditions 
(5 % CO2, 37 ˚C). After 24 h,48 h, 72 h, 96 h or 120 h, 
respectively. 10 μL CCK-8(Dojindo, Kumamoto, Japan) 
solution was added in each well respectively and the 
mixtures were incubated for 1 h. The absorbance (optical 
density, OD) was read with a universal micro plate reader 
(BioTek, Winooski, VT, USA) at 450nm. The percentage 
of growth inhibition rate was calculated by the formula: 
[1-(mean OD of experimental group – mean OD of blank 
control group)/( mean OD of Non-transfection group – 
mean OD of blank control group)] ×100%.
Soft agar cloning method
1.2 % Agarose (Invitrogen, Carlsbad, CA, USA) and 
0.7% agarose were used, respectively, as upper stratum 
and underlay. The 104 cells in each group were treated 
with supplemented with culture medium (10% fetal bovine 
serum and pre-warmed DMEM medium). Then the above 
cells were plated in 60mm dishes. Specifically, before 
the cells were seeded in the plates, an equal volume of 
1.2% argorse contained was added to the plates. When the 
underlay agarose solidified at room temperature, the above 
cells was seeded in plates in a mixture of 0.7 % argorse 
and culture medium. Then each plate was incubated 
in incubator (37°C, 5 % CO
2
) for 15 d. The clones 
(approximately 50 cells in each clone) were identified and 
counted under the microscope (DM3000, Leica, Solms, 
Germany).
Flow cytometry analysis of cell cycle
Cells (1 × 104) of each group were collected into 
centrifugal tubes, washed twice with PBS, suspended with 
the culture medium and centrifuged at 1000 rpm for 5 min. 
Cells were then washed with 70 % ethanol and centrifuged 
at 1000 rpm for 5 min for flow cytometry (FACS Vantage 
SE, Becton Dickinson and Company, Franklin Lakes, 
NJ, USA). The proliferation index(PI) was measured 
according to: PI=(G2+S) /(G1+S+G2).
Item Value
Type of search MS/MS Ion search
Enzyme SemiTrypsin
Fragment Mass 
Tolerance
±0.1Da
Mass Values Monoisotopic
Variable 
modifications
Oxidation (M), Methyl (K), 
Arg->Orn ®, Acetyl (K)
Peptide Mass 
Tolerance
±0.05Da
Fixed modifications Carbamidometh®®
Instrument Type ESI-QUAD-TOF
Database IPI human (91464 sequences)
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Construction of the tumor transplantation model
LOVO cells (1×107/mL) collected from each group 
were injected into armpits of nude mice. Nude mice 
were placed in the Specific Pathogen-Free(SFP) feeding 
room (20-26°C, 12 h dim and 12 h light) of the animal 
experimental center in Chongqing Medical University. 
After 2 weeks, mice were weighted and sacrificed. Then 
the transplant subcutaneous sarcomas were harvested and 
the tissue proteins were exacted from these excised tumors 
for detection of the expression of proteins of interest.
Quantitative real-time PCR
Quantitative real-time PCR was used to determine 
the relative expression levels of P300 MRNA. RNA was 
extracted according to the manual for the Trizol reagent 
(Takara, Dalian, China). Then, complementary DNA was 
synthesized with the directions of the PrimeScriptTMRT 
reagent Kit with GDNA Eraser (Perfect Real Time) 
(Takara, Dalian, China). The GAPDH gene was used as 
reference to normalize the expression of the transcript. The 
primers were designed by Sangon Biotech Co (Shanghai, 
China), as follows: P300, 5’-TTCAAACGCCGAGTC 
TTCTT-3’(F) and 5’-GCTGCTGTTGGCATAGG3’(R); 
GAPD,5’-GGTGAACGCTTGAACG-3’(F) and 
5’-TGTTAGTGGGGTCTCC-3’(R). Each 25 μL PCR 
master mix included 2.0 μL CDNA template (<100 ng), 
1.0 μL forward primer (10 μM),1.0 μL reverse primer (10 
μM), 12.5 μL SYBR Premix Ex Taq and 8.5 μl RNase-free 
H
2
O. The subsequent quantitative real-time PCR followed 
the directions of the SYBR Premix Ex TaqTM(Takara, 
Dalian, China) as follows:: pre-denaturation at 95 °C for 
30 s, denaturation 40 cycles at 95 °C for 5s, annealing 
at 58 °C for 20 s and elongation at 72 °C for 20 s. The 
amplification efficiency in each sample was greater than 
99%.2-△△Ct and the absolute value of the slope in each 
sample was greater than 0.1.
Histone acetyltransferase assay
A kit which used fluorescence for quantitative 
measurement of the histone acetyltransferase activity 
of P300 (GenMed scientific inc, Minneapolis, MN, 
USA) was used. The assay was followed according to 
the manufacturer’s protocol. The fluorescence intensity 
value of each group was measured by the fluorescence 
microplate reader.
Western blot analysis
The total or nuclear proteins of cells and nude mouse 
transplantation tumors of the colorectal cancers were 
extracted using a total and nuclear protein extraction kit 
(Beyotime, Shanghai, China). The concentration of protein 
was detected with a BCA protein assay kit (Beyotime). 
Then, proteins were separated by a SDS-PAGE gel and 
transferred to Poly (vinylidene fluoride)(PVDF) membranes 
(Millipore, MA, USA) by electrophoresis. The membranes 
were blocked with 5% non-fat milk for 1 h and incubated 
with primary antibodies against c-myc (Santa Cruz 
Biotechnology), cyclinD1(Proteintech Group, Chicago, IL, 
USA), β-actin (Bioss, Shanghai, China) at 4 °C overnight 
respectively. Peroxidase-conjugated goat anti-rabbit IgG 
(Bioss) was used to incubate membranes for 2 h at room 
temperature. Finally, the membranes were assessed using 
enhanced chemiluminescence reagents (ECL) (Beyotime) 
and analyzed with Quantity One software.
Co-immunoprecipitation
Lysates from each group were generated with the Piece 
Co-IP Kit (Thermo Scientific, Bonn, Germany). Then the co-
immunoprecipitation (Co-IP) was carried out according to 
the manufacturer’s instructions. Briefly, the rabbit polyclonal 
β-catenin antibody (Cell Signaling Technology, Danvers, 
MA, USA) was first immobilized for 2 h onto Amino 
Link Plus coupling resin. The resin was then washed and 
incubated with lysate overnight at 4°C. Subsequently, the 
resin was washed again and then eluted by elution buffer. 
Elution buffers were collected and analyzed by Western 
blotting which used rabbit polyclonal β-catenin antibody(Cell 
Signaling Technology, Danvers, MA,USA), rabbit polyclonal 
p300 antibody antibody (Santa Cruz Biotechnology), rabbit 
polyclonal acetylated-lysine antibody(Cell Signaling 
Technology) and peroxidase-conjugated goat anti-rabbit IgG 
(Bioss). A negative control was employed in the Co-IP kit to 
assess non-specific binding.
Statistical analysis
Experiments were replicated at least thrice. Values 
were presented as mean ± standard deviation (SD) (x ± 
s). One-way ANOVA or Student’s t-test, which were 
processed by SPSS 19.0 software (SPSS, Chicago, IL, 
USA), were used to analyze the statistical significance 
between each group. A p-value less than 0.05 indicated a 
statistically significant difference.
Abbreviations
ART ADP-ribosyltransferases
ART1
Arginine-specific mono-ADP-
ribosyltranferase1
Arg;R Arginine
A Alanine
K Lysine
H3 Histone 3
BSD Blasticidin
PARP1 Poly(ADP-ribose) polymerase 1
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NAD+ Nicotine-amide adenine dinucleotide
CTBP
N-[4-Chloro-3-(trifluoromethyl)
phenyl]-2-ethoxy-6-
pentadecylbenzamide
ADP Adenosine diphosphate
CBP CREB-binding protein
CRC Colon carcinoma
Q-PCR Quantitative real-time PCR
CCK-8 Cell counting kit-8
ECL Enhanced chemiluminescence
PVDF Polyvinylidene difluoride
Co-IP Co-immunoprecipitation
SFP Specific Pathogen Free
SDPS-PAGE Sodiumdodecylsulfate polyacrylamide gel electrophoresis
TCF4 transcription factor 4
MOI Multiplicity of infection
OD Optical density
(SD) (x ± s) Mean ± standard deviation
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